Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC Immunotherapy for Grass and Cupressaceae Allergy
NCT04898283Phase 3Recruiting
- Sponsor
- Inmunotek
- Start
- May 2021
- Primary completion
- Oct 2026
- Modality
- Subcutaneous Immunotherapy, Sublingual Immunotherapy
- Countries
- 1
01
Overview
A Phase 3 trial of polymerized grass pollen extract, polymerized juniperus oxycedrus pollen extract in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC), allergic asthma, sponsored by Inmunotek. Started May 2021; status: recruiting.
02
Drugs
polymerized grass pollen extractpolymerized juniperus oxycedrus pollen extract
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)allergic asthma
Beyond the preview
Go deeper on NCT04898283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04898283.